Amedisys, Inc. (NASDAQ:AMED) Receives $100.75 Average Price Target from Brokerages

Shares of Amedisys, Inc. (NASDAQ:AMED - Get Free Report) have received a consensus recommendation of "Hold" from the five analysts that are covering the company, Marketbeat.com reports. Four research analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $100.75.

AMED has been the topic of a number of recent research reports. Stephens restated an "equal weight" rating and set a $101.00 price target on shares of Amedisys in a report on Tuesday, March 4th. Wall Street Zen downgraded Amedisys from a "strong-buy" rating to a "buy" rating in a research note on Saturday. Finally, Royal Bank of Canada reissued an "outperform" rating and set a $100.00 price objective on shares of Amedisys in a report on Wednesday, April 16th.

Amedisys Stock Up 0.6%

Shares of AMED traded up $0.56 during midday trading on Friday, reaching $93.99. 205,629 shares of the stock were exchanged, compared to its average volume of 417,095. The company has a market cap of $3.08 billion, a price-to-earnings ratio of 37.30, a P/E/G ratio of 1.78 and a beta of 0.96. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 0.05. Amedisys has a 12-month low of $82.15 and a 12-month high of $98.95. The firm has a 50 day simple moving average of $93.37 and a 200-day simple moving average of $91.51.

Amedisys (NASDAQ:AMED - Get Free Report) last released its quarterly earnings data on Wednesday, April 23rd. The health services provider reported $1.25 EPS for the quarter, topping analysts' consensus estimates of $1.13 by $0.12. The firm had revenue of $594.78 million for the quarter, compared to the consensus estimate of $597.43 million. Amedisys had a return on equity of 12.20% and a net margin of 3.57%. The firm's revenue was up 4.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.03 earnings per share. Research analysts forecast that Amedisys will post 4.4 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in Amedisys by 0.3% during the fourth quarter. Vanguard Group Inc. now owns 3,216,120 shares of the health services provider's stock valued at $291,992,000 after acquiring an additional 10,817 shares during the period. Pentwater Capital Management LP lifted its position in shares of Amedisys by 14.0% during the 1st quarter. Pentwater Capital Management LP now owns 1,345,000 shares of the health services provider's stock worth $124,587,000 after purchasing an additional 165,000 shares during the last quarter. Alpine Associates Management Inc. boosted its stake in Amedisys by 11.7% during the 1st quarter. Alpine Associates Management Inc. now owns 992,120 shares of the health services provider's stock valued at $91,900,000 after purchasing an additional 104,000 shares during the period. Norges Bank bought a new stake in Amedisys during the 4th quarter valued at approximately $83,061,000. Finally, TIG Advisors LLC grew its holdings in Amedisys by 14.5% in the 1st quarter. TIG Advisors LLC now owns 836,417 shares of the health services provider's stock valued at $77,477,000 after buying an additional 106,002 shares during the last quarter. Institutional investors own 94.36% of the company's stock.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.